United States · Platforms & data · Stocktwits
SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
Detailed summary
SMMT shares plunged 20% overnight late Sunday after the FDA rejected its Ivonescimab-plus-chemotherapy application for a lung cancer indication.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)




